Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

DECEMBER 15, 2021

A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. “I agree with the committee that the preliminary findings from clinical trials — although still in early phases — evaluated by the panel are promising,” the decision’s author said.

Clinical Trials 52

Clinical Trials Conditions Supply Chain Environment 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. 3 Nature Aging | VOL 1 | July 2021 | p. 616–623.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

MMJ Recs

JULY 30, 2024

Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Looking ahead, the future of medical cannabis in PTSD treatment hinges on overcoming these challenges.

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

Veriheal

JUNE 29, 2022

While 233 participants might sound low, it is still the largest number of humans to participate in a psilocybin-based clinical trial. Adverse Events : This finding category refers to suicidal ideation and intentional self-injury, which were seen in all of the treatment groups.

Clinical Trials 104

Clinical Trials Blood Pressure Treatment Therapy 104

Cannabis Law Report

AUGUST 17, 2021

Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 9, 2021

Investors may register for the conference at the event website. The live and archived webcast will be available for 90 days after the event. MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. During this presentation, Chris Chapman, M.D., 646) 421-9523.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.” ” About PsyBio Therapeutics Corp.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Veriheal

MAY 3, 2022

The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size. a necessary question to address as medical marijuana becomes more accessible. Daily Cannabis Use as a Disqualifier.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

MMJ Recs

JULY 11, 2024

It is often caused by life events such as stress, anxiety, or a significant change in routine. It can be caused by a variety of factors, including medical conditions, psychological issues, or environmental factors. It can be caused by underlying health conditions, medications, or psychological factors.

Sleep 111

Sleep Treatment Research and Development Therapy 111

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

SEPTEMBER 22, 2021

Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. The principal objective of Programme 3 is to identify a drug candidate(s) for neuropathic pain conditions.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JULY 29, 2021

of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinical trials in humans and to commercialize these products. The levels of these compounds in dried mushrooms are only 0.2% – 1.0% Nova Mentis Life Science Corp.

Clinical Trials 105

Clinical Trials Conditions Packaging Events 105

Cannabis Law Report

JULY 27, 2021

The longitudinal study showed that individuals who used artisanal cannabidiol (CBD) products reported better quality of life, lower psychiatric symptom severity and fewer medication-related adverse events compared with those not using CBD. This study represents a refreshing collaboration of scientists, clinicians, patients and advocates.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

The Joint Blog

JUNE 2, 2020

According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions. Adverse events were mostly mild and resolved spontaneously.

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. Logo – [link]. SOURCE SciSparc Ltd.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. The founding co-chairs are Andrew Monte, M.D., and Arjun Chanmugam, M.D., September 30, 2021. . .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

NOVEMBER 18, 2021

Nadav Kidron, Oramed CEO and Oravax Chairman, and Rodrigo Herrera, Genomma Lab Chairman, will hold a joint press event today, Thursday, November 18, 2021 at 11:00 am EST. The live press event will be available via Zoom. Oravax is also preparing to commence clinical trials in Israel.”. 19 vaccine candidate in Mexico.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

JUNE 8, 2021

The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

MMJ Recs

JULY 3, 2024

The prevalence of anxiety disorders and stress-related conditions has risen significantly in recent decades. Additionally, CBD has anti-inflammatory and antioxidant properties, which may contribute to its therapeutic effects on stress-related conditions. Environmental stressors can also trigger and perpetuate anxiety and stress.

CBD 52

CBD Research and Development Clinical Trials THC 52

Cannabis Law Report

AUGUST 26, 2022

Apart from this, various clinical trials are done for multiple conditions. Seizures and epilepsy are serious medical conditions. Across the globe, up to 65 million people suffer from these conditions. The triggers are events that happen before the seizure starts. It has been predicted to reach about $47.22

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Project CBD

MAY 3, 2023

CannMed: For what conditions do you think CBG has the most promise? Psoriasis is a well-known condition where people get not only joint pain but they also get these thick red patches and scales on their skin. It can be a very difficult condition. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

AUGUST 24, 2021

Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

OCTOBER 15, 2021

PAOG’s RespRx research has shown effectiveness in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. RespRx, in addition to its clinical research with COPD, has been engaged in select, non-clinical trials to treat cancer and demonstrated effectiveness.

Treatment 52

Treatment Research and Development CBD eCommerce 52

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

SEPTEMBER 22, 2021

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. Can-Fite BioPharma. Motti Farbstein.

Clinical Trials 52

Clinical Trials Treatment Business Events 52

Cannabis Law Report

JUNE 7, 2021

Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Brett Maas. 646-536-7331. brett@haydenir.com www.haydenir.com. Media Contact: Will Johnson.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

CannaMD

MAY 25, 2021

The cannabinoid receptor known as CB1 , which occurs in heavy concentration in the brain, was identified as playing a role in pathophysiological events ranging from memory deficits to neurodegenerative disorders. In their summary, the study’s authors noted that. CBD alone is sufficiently effective in enhancing fracture healing.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

JANUARY 3, 2022

The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study at a single site in the Netherlands to evaluate ANEB-001 in the inhibition of THC-induced effects. The new trial design anticipates enrolling a total of 60 patients in Part A, randomized 1:1:1 between 50mg of ANEB-001, 100mg of ANEB-001 and placebo.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

OCTOBER 5, 2021

Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com. Media: media@mymd.com.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

NOVEMBER 1, 2021

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. Can-Fite BioPharma. Motti Farbstein.

Clinical Trials 52

Clinical Trials Research and Development Treatment Business 52

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. Robert Schatz. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8